Jasper Therapeutics completes Kira acquisition, raises $132M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Jasper Therapeutics Announces Merger with Kira Pharmaceuticals
July 16, 2026 5:15 PM EDTCombined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disordersÂ
Concurrent $132 million private investment with participation from leading life sciences investors and Mirador Therapeutics
Kira out-licenses KP-301, a long-acting anti-C5a monoclonal antibody, and KP-402, a small molecule C5a receptor antagonist, to Mirador Therapeutics, for $12 million upon signing and potential development and sales milestone payments
Combined financing and transactions expected to fund combined company operations through the second half of 2028, including multiple clinical milestones
... More